

77. **Comin-Colet J**, Sánchez-Corral M, Alegre-Sancho J, *et al*. Complete heart block in an adult with systemic lupus erythematosus and recent onset of hydroxychloroquine therapy. *Lupus* 2001;**10**:59–62.
78. **Keating R**, Bhatia S, Amin S, *et al*. Hydroxychloroquine-induced cardiotoxicity in a 39-year-old woman with systemic lupus erythematosus and systolic dysfunction. *J Am Soc Echocardiogr* 2005;**18**:981.
79. **Nord J**, Shah P, Rinaldi R, *et al*. Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. *Semin Arthritis Rheum* 2004;**33**:336–51.
80. **Ratliff N**, Estes M, Myles J, *et al*. Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy. *N Engl J Med* 1987;**316**:191–3.
81. **McAllister HJ**, Ferrans V, Hall R, *et al*. Chloroquine-induced cardiomyopathy. *Arch Pathol Lab Med* 1987;**111**:953–6.
82. **Naqvi T**, Luthringer D, Marchevsky A, *et al*. Chloroquine-induced cardiomyopathy—echocardiographic features. *J Am Soc Echocardiogr* 2005;**18**:383–7.
83. **Richards A**. Hydroxychloroquine myopathy. *J Rheumatol* 1998;**25**:1642–3.
84. **Malcangi G**, Fraticelli P, Palmieri C, *et al*. Hydroxychloroquine-induced seizure in a patient with systemic lupus erythematosus. *Rheumatol Int* 2000;**20**:31–3.
85. **Sabbagh M**. Diplopia in a patient under hydroxychloroquine for systemic lupus erythematosus. *Rev Rhum Engl Ed* 1997;**64**:65.
86. **Sghirlanzoni A**, Mantegazza R, Mora M, *et al*. Chloroquine myopathy and myasthenia-like syndrome. *Muscle Nerve* 1988;**11**:114–19.
87. **Tristano A**, Falcón L, Willson M, *et al*. Seizure associated with chloroquine therapy in a patient with systemic lupus erythematosus. *Rheumatol Int* 2004;**24**:315–16.
88. **Reynaert S**, Setterfield J, Black M. Hydroxychloroquine-induced pigmentation in two patients with systemic lupus erythematosus. *J Eur Acad Dermatol Venereol* 2006;**20**:487–8.
89. **Jiménez-Alonso J**, Tercedor J, Jáimez L, *et al*. Antimalarial drug-induced aquagenic-type pruritus in patients with lupus. *Arthritis Rheum* 1998;**41**:744–5.
90. **Holme S**, Holmes S. Hydroxychloroquine-induced pruritus. *Acta Derm Venereol* 1999;**79**:333.
91. **Johansen P**, Gran J. Ototoxicity due to hydroxychloroquine: report of two cases. *Clin Exp Rheumatol* 1998;**16**:472–4.
92. **Muslimani A**, Spiro T, Chaudhry A, *et al*. Secondary myelodysplastic syndrome after hydroxychloroquine therapy. *Ann Hematol* 2007;**86**:531–4.
93. **Makin A**, Wendon J, Fitt S, *et al*. Fulminant hepatic failure secondary to hydroxychloroquine. *Gut* 1994;**35**:569–70.
94. **Levy M**, Buskila D, Gladman D, *et al*. Pregnancy outcome following first trimester exposure to chloroquine. *Am J Perinatol* 1991;**8**:174–8.
95. **Parke A**, West B. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. *J Rheumatol* 1996;**23**:1715–18.
96. **Buchanan N**, Toubi E, Khamashta M, *et al*. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. *Ann Rheum Dis* 1996;**55**:486–8.
97. **Klinger G**, Morad Y, Westall C, *et al*. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. *Lancet* 2001;**358**:813–14.
98. **Costedoat-Chalumeau N**, Amoura Z, Duhaut P, *et al*. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. *Arthritis Rheum* 2003;**48**:3207–11.
99. **Borba E**, Turrini-Filho J, Kuruma K, *et al*. Chloroquine gestational use in systemic lupus erythematosus: assessing the risk of child ototoxicity by pure tone audiometry. *Lupus* 2004;**13**:223–7.
100. **Motta M**, Tincani A, Faden D, *et al*. Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. *J Perinatol* 2005;**25**:86–9.
101. **Cimaz R**, Brucato A, Meregalli E, *et al*. Electroretinograms of children born to mothers treated with hydroxychloroquine during pregnancy and breast-feeding: comment on the article by Costedoat-Chalumeau *et al*. *Arthritis Rheum* 2004;**50**:3056–7.
102. **James J**, Kim-Howard X, Bruner B, *et al*. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. *Lupus* 2007;**16**:401–9.
103. **Ruiz-Irastorza G**, Ugarte A, Egurbide M, *et al*. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. *Ann Rheum Dis* 2007;**66**:815–17.

Correction

There was an error in a letter published in the November issue of the journal (Berger CT, Recher M, Steiner U, Hauser TM. A patient's wish: anakinra in pregnancy. *Ann Rheum Dis* 2009;**68**:1794–5). It states that MR and US contributed equally. It should say that CTB and MR contributed equally.

doi:10.1136/ard.2008.105833corr1